| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiac Resynchronization Therapy | 46 | 2026 | 96 | 13.210 |
Why?
|
| Bundle of His | 28 | 2026 | 63 | 8.810 |
Why?
|
| Bundle-Branch Block | 29 | 2026 | 68 | 7.900 |
Why?
|
| Electrocardiography | 37 | 2026 | 527 | 5.370 |
Why?
|
| Defibrillators, Implantable | 23 | 2026 | 190 | 5.240 |
Why?
|
| Heart Failure | 35 | 2026 | 1491 | 5.190 |
Why?
|
| Cardiac Pacing, Artificial | 20 | 2025 | 116 | 4.800 |
Why?
|
| Atrial Fibrillation | 19 | 2024 | 460 | 4.070 |
Why?
|
| Heart Conduction System | 18 | 2025 | 143 | 3.600 |
Why?
|
| Tachycardia, Ventricular | 19 | 2025 | 180 | 3.220 |
Why?
|
| Arrhythmias, Cardiac | 16 | 2025 | 236 | 3.150 |
Why?
|
| Catheter Ablation | 25 | 2025 | 381 | 2.970 |
Why?
|
| Heart Rate | 14 | 2026 | 534 | 2.460 |
Why?
|
| Pacemaker, Artificial | 10 | 2025 | 119 | 2.290 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 12 | 2024 | 85 | 1.950 |
Why?
|
| Bradycardia | 5 | 2025 | 51 | 1.630 |
Why?
|
| Heart Ventricles | 15 | 2025 | 664 | 1.600 |
Why?
|
| Treatment Outcome | 56 | 2026 | 9682 | 1.580 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 8 | 2026 | 20 | 1.370 |
Why?
|
| Ventricular Function, Left | 12 | 2026 | 540 | 1.350 |
Why?
|
| Stroke Volume | 7 | 2025 | 464 | 1.290 |
Why?
|
| Humans | 121 | 2026 | 97883 | 1.130 |
Why?
|
| Death, Sudden, Cardiac | 6 | 2026 | 67 | 1.080 |
Why?
|
| Cardiac Catheters | 2 | 2025 | 20 | 1.050 |
Why?
|
| Aged | 64 | 2026 | 21702 | 1.010 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 4 | 2024 | 25 | 1.000 |
Why?
|
| Electric Countershock | 4 | 2024 | 77 | 0.980 |
Why?
|
| Echocardiography | 10 | 2025 | 783 | 0.940 |
Why?
|
| Cardiac Catheterization | 3 | 2025 | 307 | 0.920 |
Why?
|
| Action Potentials | 6 | 2026 | 611 | 0.910 |
Why?
|
| Anti-Arrhythmia Agents | 3 | 2019 | 77 | 0.850 |
Why?
|
| Heart Septum | 3 | 2024 | 45 | 0.800 |
Why?
|
| Male | 71 | 2026 | 46992 | 0.790 |
Why?
|
| Middle Aged | 51 | 2026 | 29353 | 0.790 |
Why?
|
| Female | 72 | 2026 | 51464 | 0.790 |
Why?
|
| Registries | 7 | 2026 | 1120 | 0.780 |
Why?
|
| Body Surface Potential Mapping | 5 | 2021 | 34 | 0.750 |
Why?
|
| Mitral Valve Insufficiency | 4 | 2019 | 179 | 0.740 |
Why?
|
| Cardiomyopathies | 7 | 2020 | 315 | 0.730 |
Why?
|
| Heart Atria | 4 | 2024 | 255 | 0.700 |
Why?
|
| Prospective Studies | 23 | 2024 | 4798 | 0.700 |
Why?
|
| Atrioventricular Block | 4 | 2024 | 33 | 0.680 |
Why?
|
| Anticoagulants | 2 | 2023 | 483 | 0.610 |
Why?
|
| Purkinje Fibers | 1 | 2019 | 28 | 0.580 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2019 | 23 | 0.580 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2019 | 63 | 0.570 |
Why?
|
| Retrospective Studies | 29 | 2025 | 10947 | 0.550 |
Why?
|
| Atrioventricular Node | 5 | 2024 | 37 | 0.510 |
Why?
|
| Cicatrix | 4 | 2024 | 78 | 0.500 |
Why?
|
| Ventricular Function, Right | 1 | 2017 | 146 | 0.490 |
Why?
|
| Follow-Up Studies | 19 | 2026 | 4023 | 0.490 |
Why?
|
| Atrial Flutter | 4 | 2020 | 45 | 0.470 |
Why?
|
| Spinal Cord Stimulation | 1 | 2015 | 20 | 0.460 |
Why?
|
| Surgical Procedures, Operative | 1 | 2018 | 223 | 0.450 |
Why?
|
| Syncope, Vasovagal | 2 | 2025 | 10 | 0.430 |
Why?
|
| Hospitalization | 4 | 2018 | 982 | 0.420 |
Why?
|
| Cause of Death | 1 | 2015 | 278 | 0.420 |
Why?
|
| Ventricular Fibrillation | 4 | 2024 | 73 | 0.380 |
Why?
|
| Streptococcal Infections | 1 | 2012 | 57 | 0.370 |
Why?
|
| Incidence | 7 | 2024 | 1776 | 0.360 |
Why?
|
| Risk Factors | 15 | 2026 | 6224 | 0.360 |
Why?
|
| Equipment Failure | 1 | 2012 | 119 | 0.360 |
Why?
|
| Myocarditis | 1 | 2012 | 60 | 0.360 |
Why?
|
| Ventricular Dysfunction, Left | 5 | 2014 | 264 | 0.340 |
Why?
|
| Growth Differentiation Factor 10 | 1 | 2011 | 1 | 0.340 |
Why?
|
| Equipment Design | 3 | 2025 | 425 | 0.340 |
Why?
|
| Antigens, Ly | 1 | 2011 | 37 | 0.340 |
Why?
|
| Postoperative Complications | 3 | 2021 | 2680 | 0.320 |
Why?
|
| Epicardial Mapping | 2 | 2021 | 12 | 0.320 |
Why?
|
| Sick Sinus Syndrome | 2 | 2021 | 8 | 0.320 |
Why?
|
| Ventricular Remodeling | 7 | 2020 | 108 | 0.310 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2011 | 130 | 0.310 |
Why?
|
| Monitoring, Physiologic | 1 | 2011 | 263 | 0.310 |
Why?
|
| Aged, 80 and over | 13 | 2026 | 7386 | 0.300 |
Why?
|
| Device Removal | 2 | 2021 | 170 | 0.300 |
Why?
|
| Time Factors | 9 | 2026 | 5555 | 0.290 |
Why?
|
| Mitral Valve | 3 | 2020 | 229 | 0.280 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 356 | 0.280 |
Why?
|
| GTPase-Activating Proteins | 1 | 2008 | 71 | 0.270 |
Why?
|
| Wnt Proteins | 1 | 2008 | 128 | 0.270 |
Why?
|
| Prosthesis Implantation | 3 | 2021 | 134 | 0.260 |
Why?
|
| Predictive Value of Tests | 7 | 2024 | 1778 | 0.260 |
Why?
|
| Recurrence | 8 | 2024 | 1254 | 0.250 |
Why?
|
| Risk Assessment | 8 | 2026 | 2580 | 0.250 |
Why?
|
| beta Catenin | 1 | 2008 | 267 | 0.240 |
Why?
|
| Myocardial Ischemia | 4 | 2019 | 142 | 0.240 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2007 | 146 | 0.240 |
Why?
|
| United States | 11 | 2026 | 8184 | 0.240 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2020 | 151 | 0.240 |
Why?
|
| Ventricular Septum | 2 | 2024 | 15 | 0.230 |
Why?
|
| Cohort Studies | 5 | 2019 | 3202 | 0.230 |
Why?
|
| Primary Prevention | 1 | 2026 | 91 | 0.220 |
Why?
|
| Myocardium | 2 | 2020 | 578 | 0.210 |
Why?
|
| Membrane Proteins | 1 | 2011 | 1285 | 0.210 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2024 | 28 | 0.210 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2004 | 9 | 0.210 |
Why?
|
| Patient Selection | 2 | 2022 | 720 | 0.200 |
Why?
|
| Frailty | 1 | 2026 | 103 | 0.200 |
Why?
|
| Hemodynamics | 2 | 2024 | 745 | 0.200 |
Why?
|
| Esophageal Fistula | 1 | 2023 | 13 | 0.200 |
Why?
|
| Particulate Matter | 1 | 2025 | 138 | 0.200 |
Why?
|
| Electrodes, Implanted | 3 | 2012 | 191 | 0.190 |
Why?
|
| Air Pollution | 1 | 2025 | 119 | 0.190 |
Why?
|
| Exosomes | 1 | 2024 | 66 | 0.190 |
Why?
|
| Influenza Vaccines | 1 | 2024 | 176 | 0.190 |
Why?
|
| Mental Health | 1 | 2024 | 219 | 0.190 |
Why?
|
| Medicare | 3 | 2024 | 467 | 0.180 |
Why?
|
| Feasibility Studies | 6 | 2021 | 799 | 0.180 |
Why?
|
| Microfluidics | 1 | 2022 | 60 | 0.180 |
Why?
|
| Vaccination | 1 | 2024 | 323 | 0.180 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 478 | 0.180 |
Why?
|
| Heart-Assist Devices | 4 | 2018 | 916 | 0.180 |
Why?
|
| Ventricular Premature Complexes | 1 | 2021 | 14 | 0.170 |
Why?
|
| Treatment Failure | 3 | 2017 | 299 | 0.170 |
Why?
|
| Exercise | 1 | 2025 | 380 | 0.170 |
Why?
|
| Prognosis | 5 | 2023 | 4112 | 0.170 |
Why?
|
| Arrhythmogenic Right Ventricular Dysplasia | 1 | 2021 | 11 | 0.170 |
Why?
|
| Prosthesis-Related Infections | 1 | 2021 | 62 | 0.160 |
Why?
|
| Electrophysiology | 1 | 2021 | 384 | 0.160 |
Why?
|
| Crohn Disease | 2 | 2007 | 844 | 0.160 |
Why?
|
| Animals | 6 | 2025 | 28899 | 0.160 |
Why?
|
| Gadolinium | 1 | 2020 | 95 | 0.160 |
Why?
|
| Muscle, Skeletal | 1 | 2024 | 521 | 0.160 |
Why?
|
| Global Health | 2 | 2021 | 215 | 0.160 |
Why?
|
| Infection Control | 1 | 2021 | 134 | 0.160 |
Why?
|
| Vena Cava, Superior | 1 | 2020 | 54 | 0.160 |
Why?
|
| Machine Learning | 1 | 2024 | 406 | 0.160 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 2008 | 0.160 |
Why?
|
| Pulmonary Veins | 2 | 2012 | 118 | 0.160 |
Why?
|
| Ultrasonography, Interventional | 1 | 2020 | 126 | 0.150 |
Why?
|
| Single-Blind Method | 1 | 2019 | 159 | 0.140 |
Why?
|
| Neurons | 2 | 2024 | 1619 | 0.140 |
Why?
|
| Tachycardia | 1 | 2018 | 36 | 0.140 |
Why?
|
| Inferior Wall Myocardial Infarction | 1 | 2018 | 2 | 0.140 |
Why?
|
| Computer Security | 1 | 2018 | 18 | 0.140 |
Why?
|
| Myocardial Contraction | 1 | 2019 | 193 | 0.140 |
Why?
|
| Computer Simulation | 1 | 2022 | 1145 | 0.130 |
Why?
|
| Quality of Life | 2 | 2024 | 1891 | 0.130 |
Why?
|
| Thromboembolism | 1 | 2018 | 123 | 0.130 |
Why?
|
| Intensive Care Units | 1 | 2021 | 473 | 0.130 |
Why?
|
| Forecasting | 2 | 2015 | 295 | 0.120 |
Why?
|
| Cardiology | 1 | 2017 | 124 | 0.120 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 473 | 0.120 |
Why?
|
| Glomerular Filtration Barrier | 1 | 2015 | 1 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 872 | 0.110 |
Why?
|
| Coronary Angiography | 2 | 2014 | 237 | 0.110 |
Why?
|
| Disease-Free Survival | 5 | 2017 | 1193 | 0.110 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2014 | 32 | 0.100 |
Why?
|
| Adult | 9 | 2025 | 29453 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2017 | 682 | 0.100 |
Why?
|
| Cardiac Conduction System Disease | 2 | 2023 | 9 | 0.100 |
Why?
|
| Heart Valve Diseases | 1 | 2014 | 103 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2017 | 520 | 0.100 |
Why?
|
| Brain | 1 | 2023 | 2429 | 0.090 |
Why?
|
| Walking | 1 | 2014 | 113 | 0.090 |
Why?
|
| Pharyngitis | 1 | 2012 | 17 | 0.090 |
Why?
|
| Creatine Kinase | 1 | 2012 | 51 | 0.090 |
Why?
|
| Streptococcus pyogenes | 1 | 2012 | 37 | 0.090 |
Why?
|
| Heart Failure, Systolic | 1 | 2012 | 5 | 0.090 |
Why?
|
| Chest Pain | 1 | 2012 | 44 | 0.090 |
Why?
|
| Troponin T | 1 | 2012 | 42 | 0.090 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2014 | 192 | 0.090 |
Why?
|
| Stem Cell Transplantation | 1 | 2013 | 194 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 268 | 0.090 |
Why?
|
| Motor Activity | 1 | 2014 | 328 | 0.090 |
Why?
|
| Prosthesis Design | 2 | 2024 | 308 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2024 | 1995 | 0.090 |
Why?
|
| Tachycardia, Paroxysmal | 1 | 2011 | 3 | 0.080 |
Why?
|
| Smad3 Protein | 1 | 2011 | 25 | 0.080 |
Why?
|
| RNA, Neoplasm | 1 | 2011 | 87 | 0.080 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2011 | 51 | 0.080 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2017 | 1302 | 0.080 |
Why?
|
| Survival Rate | 3 | 2026 | 2040 | 0.080 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 310 | 0.080 |
Why?
|
| Renal Dialysis | 1 | 2013 | 356 | 0.080 |
Why?
|
| Hypertension, Pulmonary | 1 | 2014 | 382 | 0.080 |
Why?
|
| Mice | 3 | 2024 | 12698 | 0.070 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2011 | 121 | 0.070 |
Why?
|
| Surveys and Questionnaires | 4 | 2024 | 3021 | 0.070 |
Why?
|
| Patient Care Team | 1 | 2012 | 318 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2013 | 445 | 0.070 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 396 | 0.070 |
Why?
|
| Biomarkers | 2 | 2012 | 2016 | 0.070 |
Why?
|
| Signal Transduction | 2 | 2011 | 3623 | 0.070 |
Why?
|
| Axin Protein | 1 | 2008 | 4 | 0.070 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2008 | 44 | 0.070 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2008 | 47 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 1567 | 0.070 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2008 | 71 | 0.070 |
Why?
|
| Cytosol | 1 | 2008 | 193 | 0.070 |
Why?
|
| Young Adult | 3 | 2021 | 7504 | 0.070 |
Why?
|
| Age Factors | 1 | 2012 | 1960 | 0.070 |
Why?
|
| Contrast Media | 2 | 2024 | 1011 | 0.070 |
Why?
|
| Base Sequence | 1 | 2011 | 2222 | 0.070 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 1605 | 0.060 |
Why?
|
| Behavior | 1 | 2007 | 86 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 2783 | 0.060 |
Why?
|
| Interprofessional Relations | 1 | 2007 | 122 | 0.060 |
Why?
|
| Perception | 1 | 2007 | 187 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2014 | 902 | 0.060 |
Why?
|
| Clinical Clerkship | 1 | 2007 | 116 | 0.060 |
Why?
|
| Mice, Knockout | 1 | 2011 | 2206 | 0.060 |
Why?
|
| Zebrafish | 1 | 2008 | 353 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 1394 | 0.060 |
Why?
|
| Ethics, Medical | 1 | 2007 | 292 | 0.050 |
Why?
|
| Comorbidity | 2 | 2021 | 1032 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2008 | 448 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2011 | 2063 | 0.050 |
Why?
|
| Ventricular Pressure | 1 | 2024 | 41 | 0.050 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2024 | 12 | 0.050 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2024 | 18 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 1944 | 0.050 |
Why?
|
| Syncope | 1 | 2024 | 30 | 0.050 |
Why?
|
| Heart Injuries | 1 | 2024 | 23 | 0.050 |
Why?
|
| Prevalence | 2 | 2018 | 1384 | 0.050 |
Why?
|
| Nerve Growth Factors | 1 | 2024 | 54 | 0.050 |
Why?
|
| Fluoroscopy | 1 | 2024 | 138 | 0.050 |
Why?
|
| Cell Line | 1 | 2008 | 2482 | 0.050 |
Why?
|
| Models, Biological | 1 | 2011 | 1805 | 0.050 |
Why?
|
| Atropine | 1 | 2023 | 53 | 0.050 |
Why?
|
| Fibronectins | 1 | 2024 | 104 | 0.050 |
Why?
|
| Electrophysiological Phenomena | 1 | 2023 | 51 | 0.050 |
Why?
|
| Heart Block | 1 | 2023 | 34 | 0.050 |
Why?
|
| Electrodes | 1 | 2023 | 90 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2024 | 185 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 3604 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1286 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2004 | 210 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2024 | 394 | 0.050 |
Why?
|
| Electric Stimulation | 1 | 2023 | 340 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2024 | 282 | 0.050 |
Why?
|
| Chemistry Techniques, Analytical | 1 | 2022 | 8 | 0.050 |
Why?
|
| Viscosity | 1 | 2022 | 52 | 0.050 |
Why?
|
| Motor Neurons | 1 | 2024 | 192 | 0.050 |
Why?
|
| Health Status | 1 | 2024 | 385 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 188 | 0.050 |
Why?
|
| Students, Medical | 1 | 2007 | 449 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2012 | 221 | 0.040 |
Why?
|
| Mortality | 1 | 2021 | 158 | 0.040 |
Why?
|
| Endocardium | 1 | 2020 | 81 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2014 | 359 | 0.040 |
Why?
|
| Vascular System Injuries | 1 | 2020 | 47 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 1094 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2024 | 604 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2012 | 1527 | 0.040 |
Why?
|
| Disease Progression | 2 | 2014 | 1609 | 0.040 |
Why?
|
| Pericardium | 1 | 2019 | 73 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 1750 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2017 | 123 | 0.030 |
Why?
|
| Heart | 1 | 2020 | 527 | 0.030 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2017 | 66 | 0.030 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2017 | 197 | 0.030 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2015 | 6 | 0.030 |
Why?
|
| Boston | 1 | 2015 | 42 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2020 | 630 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2014 | 65 | 0.030 |
Why?
|
| Tissue Survival | 1 | 2014 | 13 | 0.030 |
Why?
|
| Capillaries | 1 | 2014 | 86 | 0.030 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2014 | 39 | 0.030 |
Why?
|
| Massachusetts | 1 | 2013 | 37 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 87 | 0.020 |
Why?
|
| Cardiac Output | 1 | 2012 | 142 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 301 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 2012 | 137 | 0.020 |
Why?
|
| Child | 1 | 2023 | 7680 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 920 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1284 | 0.020 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2011 | 20 | 0.020 |
Why?
|
| Adolescent | 1 | 2004 | 10078 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 660 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2013 | 985 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 968 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1009 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 983 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 2014 | 873 | 0.020 |
Why?
|
| Observation | 1 | 2007 | 38 | 0.020 |
Why?
|
| Italy | 1 | 2007 | 113 | 0.020 |
Why?
|
| Japan | 1 | 2007 | 303 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 1125 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2007 | 889 | 0.010 |
Why?
|
| Reoperation | 1 | 2007 | 727 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2007 | 580 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2007 | 684 | 0.010 |
Why?
|